- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 CAMBRIDGE, Mass., May 29, ...

Laryngeal dystonia (LD), a rare neurological disease that significantly impacts a person's ability to speak due to uncontrollable vocal cord spasms, can have a debilitating effect on a person's social ...

When we think of movement disorders, the tremors associated with Parkinson’s disease are probably what first spring to mind. However, there are other equally debilitating and much less well-known ...

Dystonia is a neurological disorder that causes painful muscle spasms. (Photo Credit: Sebastian Kaulitzki/Science Photo Library/Getty Images) Dystonia is a movement disorder in which some of your body ...

Dystonia is a movement disorder that causes muscles to contract involuntarily, often leading to repetitive or twisting movements in different parts of the body. While the condition is not typically ...

Huntington's disease is characterized by death of striatal projection neurons. We used a Cre/Lox transgenic approach to generate an animal model in which D1 dopamine receptor (Drd1a)+ cells are ...

BACKGROUND: Dystonia is a movement disorder characterized by involuntary contractions and spasms of muscles. These actions force the body into repetitive, often twisting, movements and awkward, ...

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, launched today with a $60M Series A ...